Role of mTOR inhibitor in the cellular and humoral immune response to a booster dose of SARS-CoV-2 mRNA-1273 vaccine in kidney transplant recipients
dc.contributor.author | Pérez Flores, Isabel María | |
dc.contributor.author | Juárez Martín-Delgado, Ignacio | |
dc.contributor.author | Aiffil Meneses, Arianne S. | |
dc.contributor.author | López Gómez, Ana | |
dc.contributor.author | Calvo Romero, Natividad | |
dc.contributor.author | Rodríguez Cubillo, Beatriz | |
dc.contributor.author | Moreno de la Higuera, María Ángeles | |
dc.contributor.author | Peix Jiménez, Belén | |
dc.contributor.author | González García, Raquel | |
dc.contributor.author | Baos Muñoz, Elvira | |
dc.contributor.author | Arribi Vilela, Ana | |
dc.contributor.author | Gómez Del Moral Martín-Consuegra, Manuel María | |
dc.contributor.author | Martínez Naves, Eduardo | |
dc.contributor.author | Sánchez Fructuoso, Ana Isabel | |
dc.date.accessioned | 2024-01-10T12:16:40Z | |
dc.date.available | 2024-01-10T12:16:40Z | |
dc.date.issued | 2023-02-02 | |
dc.description.abstract | Background: Immunocompromised patients have an increased risk of developing severe COVID disease, as well as a tendency to suboptimal responses to vaccines. The objective of this study was to evaluate the specific cellular and humoral adaptive immune responses of a cohort of kidney transplant recipients (KTR) after 3 doses of mRNA-1273 vaccine and to determinate the main factors involved. Methods: Prospective observational study in 221 KTR (149 non infected), 55 healthy volunteers (HV) and 23 dialysis patients (DP). We evaluated anti-spike (by quantitative chemiluminescence immunoassay) and anti-nucleocapsid IgG (ELISA), percentage of TCD4+ and TCD8+ lymphocytes producing IFNγ against S-protein by intracellular flow cytometry after Spike-specific 15-mer peptide stimulation and serum neutralizing activity (competitive ELISA) at baseline and after vaccination. Results: Among COVID-19 naïve KTR, 54.2% developed cellular and humoral response after the third dose (vs 100% in DP and 91.7% in HV), 18% only showed cell-mediated response, 22.2% exclusively antibody response and 5.6% none. A correlation of neutralizing activity with both the IgG titer (r=0.485, p<0.001) and the percentage of S-protein-specific IFNγ-producing CD8-T cells (r=0.198, p=0.049) was observed. Factors related to the humoral response in naïve KTR were: lymphocytes count pre-vaccination >1000/mm3 [4.68 (1.72-12.73, p=0.003], eGFR>30 mL/min [7.34(2.72-19.84), p<0.001], mTOR inhibitors [6.40 (1.37-29.86), p=0.018]. Infected KTR developed a stronger serologic response than naïve patients (96.8 vs 75.2%, p<0.001). Conclusions: KTR presented poor cellular and humoral immune responses following vaccination with mRNA-1273. The immunosuppression degree and kidney function of these patients play an important role, but the only modifiable factor with a high impact on humoral immunogenicity after a booster dose was an immunosuppressive therapy including a mTOR inhibitor. Clinical trials are required to confirm these results. | |
dc.description.department | Depto. de Inmunología, Oftalmología y ORL | |
dc.description.faculty | Fac. de Medicina | |
dc.description.refereed | TRUE | |
dc.description.status | pub | |
dc.identifier.citation | Pérez-Flores I, Juarez I, Aiffil Meneses AS, Lopez-Gomez A, Romero NC, Rodriguez-Cubillo B, Moreno de la Higuera MA, Peix-Jiménez B, Gonzalez-Garcia R, Baos-Muñoz E, Vilela AA, Gómez Del Moral M, Martínez-Naves E, Sanchez-Fructuoso AI. Role of mTOR inhibitor in the cellular and humoral immune response to a booster dose of SARS-CoV-2 mRNA-1273 vaccine in kidney transplant recipients. Front Immunol. 2023 Feb 2;14:1111569. doi: 10.3389/fimmu.2023.1111569 | |
dc.identifier.doi | 10.3389/fimmu.2023.1111569 | |
dc.identifier.issn | 1664-3224 | |
dc.identifier.officialurl | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1111569/full | |
dc.identifier.relatedurl | https://pubmed.ncbi.nlm.nih.gov/36817489/ | |
dc.identifier.uri | https://hdl.handle.net/20.500.14352/92236 | |
dc.journal.title | Frontiers in Immunology | |
dc.language.iso | eng | |
dc.publisher | Frontiers Media | |
dc.rights | Attribution 4.0 International | en |
dc.rights.accessRights | open access | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject.cdu | 612.017 | |
dc.subject.keyword | COVID-19 | |
dc.subject.keyword | SARS-CoV-2 vaccine | |
dc.subject.keyword | Immune response | |
dc.subject.keyword | Kidney transplantation | |
dc.subject.keyword | mTOR | |
dc.subject.ucm | Ciencias Biomédicas | |
dc.subject.unesco | 2412 Inmunología | |
dc.title | Role of mTOR inhibitor in the cellular and humoral immune response to a booster dose of SARS-CoV-2 mRNA-1273 vaccine in kidney transplant recipients | |
dc.type | journal article | |
dc.type.hasVersion | VoR | |
dc.volume.number | 14 | |
dspace.entity.type | Publication | |
relation.isAuthorOfPublication | 20948f45-92ce-4a9e-89b4-783c9696d0a1 | |
relation.isAuthorOfPublication | 0894d58b-fe71-42aa-ad0a-19305823daa1 | |
relation.isAuthorOfPublication | 3fcc2577-06c2-47f6-bf47-25a44263702b | |
relation.isAuthorOfPublication | 759562da-31b9-467b-82a2-f88052d2a9a2 | |
relation.isAuthorOfPublication | e93526bf-b07c-4e2f-a128-2a86044d88e6 | |
relation.isAuthorOfPublication | 520f2d09-78ca-4d34-b7bc-eb333044ae32 | |
relation.isAuthorOfPublication | 52048564-29f6-4bd9-b131-6712b4fb871c | |
relation.isAuthorOfPublication.latestForDiscovery | 20948f45-92ce-4a9e-89b4-783c9696d0a1 |
Download
Original bundle
1 - 1 of 1
Loading...
- Name:
- mRNA-1273 Tx H Clínico Frontier Immunol 2023.pdf
- Size:
- 2.24 MB
- Format:
- Adobe Portable Document Format